ADCT7:15 AMADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA® Combination TrialEnrollment • Phase 1Enrollment milestone Tue, Jun 30, 2026adctherapeutics.com
ADCT7:30 AMADC Therapeutics Announces Strategic Reorganization to Support ZYNLONTA® Growth Opportunities and Regulatory Prioritiesadctherapeutics.com
ADCT4:05 PMADC Therapeutics Announces Results From LOTIS-5 Phase 3 Confirmatory Clinical Trial of ZYNLONTA® in Combination with Rituximab in Relapsed or Refractory Diffuse Large B-Cell LymphomaTrial Results • Phase 3Topline results Wed, Jun 3, 2026adctherapeutics.com
ADCT7:30 AMADC Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Updatesadctherapeutics.com
ADCT7:30 AMADC Therapeutics to Host First Quarter 2026 Financial Results Conference Call on May 4, 2026adctherapeutics.com